A pivotal publication detailing the efficacy and safety of finerenone (Kerendia) for cardiovascular events in patients with kidney disease and type 2 diabetes was released on 2021-01-01. The publication, titled "Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes," presents the findings from the FIGARO-DKD trial, which investigated finerenone in subjects diagnosed with type 2 diabetes mellitus and clinical diabetic kidney disease.
Background
Finerenone (Kerendia) was studied in the context of its potential impact on cardiovascular events in individuals suffering from both kidney disease and type 2 diabetes. This patient population faces a significantly elevated risk for adverse cardiovascular outcomes, making interventions that address this dual burden particularly important. The FIGARO-DKD trial specifically aimed to evaluate the drug's performance in subjects presenting with type 2 diabetes mellitus alongside a clinical diagnosis of diabetic kidney disease, a common and serious complication of diabetes.
Trial design
The FIGARO-DKD trial was designed to assess the efficacy and safety profile of finerenone in a specific patient cohort: individuals with type 2 diabetes mellitus and a clinical diagnosis of diabetic kidney disease. The primary focus of the investigation, as indicated by the publication's title, was on cardiovascular events. This trial aimed to provide comprehensive data on how finerenone influences these critical outcomes in this vulnerable population.
What this means
The publication of the FIGARO-DKD trial results represents a significant contribution to the medical literature concerning the management of patients with kidney disease and type 2 diabetes. Clinicians and researchers now have access to detailed data regarding the efficacy and safety of finerenone in addressing cardiovascular events within this high-risk group. This information is vital for informing treatment decisions and advancing the understanding of therapeutic strategies for diabetic kidney disease.
Source
The information regarding this pivotal publication was obtained from PubMed, a widely recognized database for biomedical literature. The article, titled "Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes," was published on 2021-01-01. Further details can be found on the pubmed.ncbi.nlm.nih.gov website, with the specific PubMed ID 34449181.